First test of new prostate cancer pill in japan
NCT ID NCT07174063
Summary
This is an early-stage study to check the safety and how the body processes a new oral drug called JSB462. It involves about 15 Japanese men whose prostate cancer has spread and who have few other treatment options. The main goal is to find a safe dose by closely monitoring patients for side effects and measuring drug levels in their blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGNagoya, Aichi-ken, 4668560, Japan
-
Novartis Investigative Site
RECRUITINGBunkyo Ku, Tokyo, 1138677, Japan
-
Novartis Investigative Site
RECRUITINGKoto Ku, Tokyo, 1358550, Japan
-
Novartis Investigative Site
RECRUITINGKobe, 650-0017, Japan
Conditions
Explore the condition pages connected to this study.